Phio Pharmaceuticals (PHIO) Change in Account Payables (2011 - 2026)
Phio Pharmaceuticals' (PHIO) quarterly Change in Account Payables came in at -$175000.0 in Q1 2026, down 200.57% YoY from $174000.0 in Q1 2025, and down 118.75% on a QoQ basis from -$80000.0 in Q4 2025.
Phio Pharmaceuticals (PHIO) Change in Account Payables (2011 - 2026) Analysis & Trends
Phio Pharmaceuticals (PHIO) has 16 years of Change in Account Payables data on file, last reported at -$175000.0 in Q1 2026.
- Quarterly Change in Account Payables fell 200.57% year-over-year to -$175000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$166000.0 (down 255.14% YoY) and the FY2025 annual result came in at $183000.0, up 145.3% from the prior year.
- Change in Account Payables fell to -$175000.0 in Q1 2026, from -$80000.0 in the prior quarter.
- In the past five years, Change in Account Payables ranged from a high of $819000.0 in Q2 2022 to a low of -$605000.0 in Q3 2022.
- A 5-year average of -$1294.1 and a median of $15000.0 in 2024 frame the typical range for Change in Account Payables.
- The widest YoY moves for Change in Account Payables: up 705.13% in 2022, down 2226.92% in 2022.
- Tracing PHIO's Change in Account Payables over 5 years: stood at $236000.0 in 2022, then jumped by 105.08% to $484000.0 in 2023, then sank by 85.74% to $69000.0 in 2024, then slumped by 215.94% to -$80000.0 in 2025, then tumbled by 118.75% to -$175000.0 in 2026.
- The last three Change in Account Payables figures came in at -$175000.0 (Q1 2026), -$80000.0 (Q4 2025), and $281000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -66.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -8.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 37.53 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Phio Pharmaceuticals | 13.77 Mn | 13.77 Mn | - | 641,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 641,000.00 |
| Jun 30, 2026 | 641,000.00 |
| Mar 31, 2026 | -175,000.00 |
| Mar 31, 2026 | -175,000.00 |
| Dec 31, 2025 | -80,000.00 |
| Dec 31, 2025 | -80,000.00 |
| Sep 30, 2025 | 281,000.00 |
| Sep 30, 2025 | 281,000.00 |
| Jun 30, 2025 | -192,000.00 |
| Jun 30, 2025 | -192,000.00 |
| Mar 31, 2025 | 174,000.00 |
| Mar 31, 2025 | 174,000.00 |
| Dec 31, 2024 | 69,000.00 |
| Dec 31, 2024 | 69,000.00 |
| Sep 30, 2024 | -151,000.00 |
| Sep 30, 2024 | -151,000.00 |
| Jun 30, 2024 | 15,000.00 |
| Jun 30, 2024 | 15,000.00 |
| Mar 31, 2024 | -337,000.00 |
| Mar 31, 2024 | -337,000.00 |